RecruitingNot ApplicableNCT06376604
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
Use of a Fasting Mimicking Diet in Patients Undergoing Chemotherapy for Gynecologic Malignancies
Sponsor
L-Nutra Inc
Enrollment
30 participants
Start Date
Sep 8, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
This study evaluates how lifestyle modifications that may be made to manage chemotherapy side effects in patients with gynecologic malignancies.
Eligibility
Sex: FEMALEMin Age: 35 YearsMax Age: 70 Years
Inclusion Criteria7
- Women
- Age 35-70 years old (both inclusive)
- Biopsy proven gynecologic malignancy
- Scheduled to or currently undergoing chemotherapy, with a minimum of 6 cycles remaining
- BMI greater than or equal to 18.5
- Adequate renal function (serum creatinine less than 1.5 times the upper limit of normal)
- Willing to adhere to a 5-day fasting mimicking diet
Exclusion Criteria7
- Pregnant or nursing mothers
- Prisoners
- Patients with diabetes or history of hypoglycemia
- Taking daily medications that cannot be safely taken without food
- History of significant or unstable cardiac disease such as congestive heart failure or history of myocardial infarction, stroke or pulmonary embolism within the last 3 months, renal failure, history of - eating disorder, dementia, psychosis, impaired physical mobility.
- Significant medical comorbidity that would be dangerous with a fasting mimicking diet.
- Any known or suspected food allergies that overlap with the FMD/Transitional diet by L-Nutra meal kit ingredients.
Interventions
OTHERFasting Mimicking Diet
Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
DRUGChemotherapy
6 cycles of standard chemotherapy for the gynecologic malignancy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06376604
Related Trials
WellSpan-THRIVE Cancer QOL Study
NCT074336605 locations
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
NCT063132031 location
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
NCT065100101 location
Survivors Uniting for Remote Guided Exercise
NCT072903091 location
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT047244991 location